Zai Lab Limited ZLAB
26.42 USD -0.01 (-0.04%)
At closeNov 12, 2026, 4:12 AM EST
26.00 -0.42 -1.59%
Pre-market · Nov 12, 4:12 AM ET
25.33 Day range 26.50
15.96 52-week range 29.02
- YTD
- +49.77%
- 1 year
- +20.09%
News
zacks.com Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High? The consensus price target hints at a 40.2% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
marketbeat.com Zai Lab Q3 Earnings Call Highlights Zai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate…
seekingalpha.com Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
zacks.com Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Zai Lab Limited (ZLAB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key…
benzinga.com Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society Symposium In the Phase 1b/2 trial, zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, demonstrated clinically meaningful responses in patients with previously treated advanced…
benzinga.com Zai Lab Q3 2026 Earnings Call Transcript Zai Lab (NASDAQ:ZLAB) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
businesswire.com Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that updated data from a Phase 1b/2 trial of…
benzinga.com Zai Lab Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $108.208M Beat $105.825M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 33.33 percent. This is a 33.33 percent decrease over losses of $(0.03) per…
businesswire.com Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026,…
benzinga.com Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3 At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of…